CAGE Bio Begins Double-Blind Clinical Trial Of Novel Topical DNA Therapy For Vitiligo
CAGE Bio has launched a randomized, double-blind, vehicle-controlled clinical trial to evaluate its novel DNA Aptamer therapy, CGB-600, for treating vitiligo. The therapy, licensed from Japan’s TAGCyx Biotechnologies, is designed to selectively bind interferon gamma and reduce autoimmune activity that destroys pigment cells. The study will enroll 36 adults with facial vitiligo, with topline results expected in Q3 2026. If successful, CGB-600 could offer a first-in-class, targeted treatment with durable re-pigmentation and fewer side effects. 
CAGE Bio Begins Double-Blind Clinical Trial Of Novel Topical DNA Therapy For Vitiligo